Role of Lenalidomide in CLL

In chronic lymphocytic leukemia (CLL), tumour cells do not form stable cognate interactions with CD4+ and CD8+ T cells for a number of reasons including an impaired clustering and activation of lymphocyte function-associated antigen-1 (LFA-1).

As well, CLL cells induce profound modifications of T-cell transcriptomes that further endanger the formation of effective immune synapses resulting in defective antitumour responses. Lenalidomide, an immunomodulatory drug, causes the downregulation of CLL ligands, restores the stabilization of effective immune synapses and rescues the function of LFA-1. To read more, click here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.